Login to Your Account


Just five months after former Sanofi SA chief Chris Viehbacher took charge of the $2 billion health care fund Gurnet Point Capital, he's launching a drug development venture dedicated to transforming undeveloped but promising molecules into a portfolio of high-quality, phase III-ready assets.

DUBLIN – Swiss orphan drug developer AB2 Bio Ltd. has obtained dramatic clinical proof of concept for its recombinant interleukin-18-binding protein (IL-18BP) therapy (tadekinig alfa), in an exceptional case involving an infant girl at risk of death from severe systemic inflammation.

Look out, big pharma. The first generation of scientists who came of age during the genomics revolution is transitioning from the classroom to the boardroom, and they're seeking to shake up the industry.
More Newco News Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: